Eris Lifesciences Ltd
₹1,358.3-0.21%Feb 27, 3:45 PM IST
ERIS•Health Technology•Pharmaceuticals: Major
Current Price
₹1,358.3-0.21%
Feb 27, 3:45 PM ISTMarket Cap₹18,545.93 Cr
Market Cap₹18,545.93 Cr
Business Overview
Eris Lifesciences Limited operates through 2 main business divisions including Domestic Branded Formulations, Sterile Injectables.
Business Hierarchy Structure for Eris Lifesciences Limited
- Eris Lifesciences Limited
- Domestic Branded Formulations
- Anti-Diabetes (Oral + Insulins)
- Oral Solid Dose (OSD)
- Glimisave
- Cyblex
- Tendia
- Zomelis
- Gluxit
- Linares
- Glura
- Insulins
- Xsulin
- Xglar
- Insugen
- Basalog
- Oral Solid Dose (OSD)
- Cardiovascular (CVD)
- ADURA
- Inspira
- Eritel
- LNBloc
- Olmin
- Crevast
- Atorsave
- Zayo
- Vitamins, Minerals & Nutrients (VMN)
- Renerve
- Tayo
- Remylin
- Nikkos
- Montana
- Filix
- Venus
- Dermatology (Derma)
- Onabet
- Halovate
- Demelan
- Psorid
- Tbis
- Picon
- SKINCARE
- CosmeCare
- DermaCare
- Biocon Immuno
- Hydroheal Nova
- Crisanew
- Efatop Hydra
- Hydroheal Soft
- Crizamont
- Strandz
- Strandz Boost
- Clearz New
- Women's Health (WHC)
- Drolute
- Montana
- Venus
- Central Nervous System (CNS)
- Altiza
- Eterna
- Cirq
- Cirq Plus
- Revlin D
- Nobix Plus
- Dugo
- Napq
- Napq Plus
- Oncology
- Biomab (Nimotuzumab)
- Canmab
- Hertraz
- Krabeva
- Abevmy
- Biocon Oncology
- Critical Care
- Nephrology
- Tacrograf
- Renodapt
- Bionesp
- Erypro
- Rest
- Anti-Diabetes (Oral + Insulins)
- Sterile Injectables
- Swiss Parenterals
- Small Volume Parenterals (SVP)
- Biocon's India Branded Business (Injectables)
- Insulins
- Critical Care
- Oncology
- Swiss Parenterals
- Domestic Branded Formulations